Steroid treatment in ARDS: A critical appraisal of the ARDS network trial and the recent literature

G. Umberto Meduri, Paul E. Marik, George P. Chrousos, Stephen M. Pastores, Wiebke Arlt, Albertus Beishuizen, Faran Bokhari, Gary Zaloga, Djillali Annane

Research output: Contribution to journalComment/debate

125 Citations (Scopus)

Abstract

Objectives: To compare the design and results of randomized trials investigating prolonged glucocorticoid treatment (≥7 days) in patients with acute lung injury-acute respiratory distress syndrome (ALI-ARDS), and review factors affecting response to therapy, including the role of secondary prevention. Design: Trials were retrieved from the Cochrane Central Register of Controlled Trials (CENTRAL). Two investigators collected data on study characteristics, treatment intervention, and outcomes. The methodological quality of trials was determined and data were analyzed with Review Manager 4.2.3. Measurements and results: Five selected trials (n = 518) consistently reported significant improvement in gas exchange, reduction in markers of inflammation, and decreased duration of mechanical ventilation and intensive care unit stay (all p < 0.05). Two early small clinical trials showed marked reductions in the relative risk (RR) of death with glucocorticoid therapy (RR = 0.14, 95% CI 0.04-0.53; p = 0.004, I2 = 0%). Three subsequent larger trials, when combined, although nominally beneficial, did not reproduce the marked reductions observed in the earlier trials (RR = 0.84; 95% CI 0.68-1.03; p = 0.09, I2 = 9.1%), but achieved a distinct reduction in the RR of death in the larger subgroup of patients (n = 400) treated before day 14 of ARDS [82/214 (38%) vs. 98/186 (52.5%), RR = 0.78; 95% CI 0.64-0.96; p = 0.02, I 2 = 0%]. Conclusions: Prolonged glucocorticoid treatment substantially and significantly improves meaningful patient-centered outcome variables, and has a distinct survival benefit when initiated before day 14 of ARDS.

Original languageEnglish (US)
Pages (from-to)61-69
Number of pages9
JournalIntensive care medicine
Volume34
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Steroids
Glucocorticoids
Therapeutics
Acute Lung Injury
Adult Respiratory Distress Syndrome
Secondary Prevention
Artificial Respiration
Intensive Care Units
Gases
Research Personnel
Clinical Trials
Inflammation
Survival

All Science Journal Classification (ASJC) codes

  • Critical Care and Intensive Care Medicine

Cite this

Steroid treatment in ARDS : A critical appraisal of the ARDS network trial and the recent literature. / Meduri, G. Umberto; Marik, Paul E.; Chrousos, George P.; Pastores, Stephen M.; Arlt, Wiebke; Beishuizen, Albertus; Bokhari, Faran; Zaloga, Gary; Annane, Djillali.

In: Intensive care medicine, Vol. 34, No. 1, 01.01.2008, p. 61-69.

Research output: Contribution to journalComment/debate

Meduri, GU, Marik, PE, Chrousos, GP, Pastores, SM, Arlt, W, Beishuizen, A, Bokhari, F, Zaloga, G & Annane, D 2008, 'Steroid treatment in ARDS: A critical appraisal of the ARDS network trial and the recent literature', Intensive care medicine, vol. 34, no. 1, pp. 61-69. https://doi.org/10.1007/s00134-007-0933-3
Meduri, G. Umberto ; Marik, Paul E. ; Chrousos, George P. ; Pastores, Stephen M. ; Arlt, Wiebke ; Beishuizen, Albertus ; Bokhari, Faran ; Zaloga, Gary ; Annane, Djillali. / Steroid treatment in ARDS : A critical appraisal of the ARDS network trial and the recent literature. In: Intensive care medicine. 2008 ; Vol. 34, No. 1. pp. 61-69.
@article{12ef993023ad43b99ec7efeba9a481e6,
title = "Steroid treatment in ARDS: A critical appraisal of the ARDS network trial and the recent literature",
abstract = "Objectives: To compare the design and results of randomized trials investigating prolonged glucocorticoid treatment (≥7 days) in patients with acute lung injury-acute respiratory distress syndrome (ALI-ARDS), and review factors affecting response to therapy, including the role of secondary prevention. Design: Trials were retrieved from the Cochrane Central Register of Controlled Trials (CENTRAL). Two investigators collected data on study characteristics, treatment intervention, and outcomes. The methodological quality of trials was determined and data were analyzed with Review Manager 4.2.3. Measurements and results: Five selected trials (n = 518) consistently reported significant improvement in gas exchange, reduction in markers of inflammation, and decreased duration of mechanical ventilation and intensive care unit stay (all p < 0.05). Two early small clinical trials showed marked reductions in the relative risk (RR) of death with glucocorticoid therapy (RR = 0.14, 95{\%} CI 0.04-0.53; p = 0.004, I2 = 0{\%}). Three subsequent larger trials, when combined, although nominally beneficial, did not reproduce the marked reductions observed in the earlier trials (RR = 0.84; 95{\%} CI 0.68-1.03; p = 0.09, I2 = 9.1{\%}), but achieved a distinct reduction in the RR of death in the larger subgroup of patients (n = 400) treated before day 14 of ARDS [82/214 (38{\%}) vs. 98/186 (52.5{\%}), RR = 0.78; 95{\%} CI 0.64-0.96; p = 0.02, I 2 = 0{\%}]. Conclusions: Prolonged glucocorticoid treatment substantially and significantly improves meaningful patient-centered outcome variables, and has a distinct survival benefit when initiated before day 14 of ARDS.",
author = "Meduri, {G. Umberto} and Marik, {Paul E.} and Chrousos, {George P.} and Pastores, {Stephen M.} and Wiebke Arlt and Albertus Beishuizen and Faran Bokhari and Gary Zaloga and Djillali Annane",
year = "2008",
month = "1",
day = "1",
doi = "10.1007/s00134-007-0933-3",
language = "English (US)",
volume = "34",
pages = "61--69",
journal = "Intensive Care Medicine",
issn = "0342-4642",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Steroid treatment in ARDS

T2 - A critical appraisal of the ARDS network trial and the recent literature

AU - Meduri, G. Umberto

AU - Marik, Paul E.

AU - Chrousos, George P.

AU - Pastores, Stephen M.

AU - Arlt, Wiebke

AU - Beishuizen, Albertus

AU - Bokhari, Faran

AU - Zaloga, Gary

AU - Annane, Djillali

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Objectives: To compare the design and results of randomized trials investigating prolonged glucocorticoid treatment (≥7 days) in patients with acute lung injury-acute respiratory distress syndrome (ALI-ARDS), and review factors affecting response to therapy, including the role of secondary prevention. Design: Trials were retrieved from the Cochrane Central Register of Controlled Trials (CENTRAL). Two investigators collected data on study characteristics, treatment intervention, and outcomes. The methodological quality of trials was determined and data were analyzed with Review Manager 4.2.3. Measurements and results: Five selected trials (n = 518) consistently reported significant improvement in gas exchange, reduction in markers of inflammation, and decreased duration of mechanical ventilation and intensive care unit stay (all p < 0.05). Two early small clinical trials showed marked reductions in the relative risk (RR) of death with glucocorticoid therapy (RR = 0.14, 95% CI 0.04-0.53; p = 0.004, I2 = 0%). Three subsequent larger trials, when combined, although nominally beneficial, did not reproduce the marked reductions observed in the earlier trials (RR = 0.84; 95% CI 0.68-1.03; p = 0.09, I2 = 9.1%), but achieved a distinct reduction in the RR of death in the larger subgroup of patients (n = 400) treated before day 14 of ARDS [82/214 (38%) vs. 98/186 (52.5%), RR = 0.78; 95% CI 0.64-0.96; p = 0.02, I 2 = 0%]. Conclusions: Prolonged glucocorticoid treatment substantially and significantly improves meaningful patient-centered outcome variables, and has a distinct survival benefit when initiated before day 14 of ARDS.

AB - Objectives: To compare the design and results of randomized trials investigating prolonged glucocorticoid treatment (≥7 days) in patients with acute lung injury-acute respiratory distress syndrome (ALI-ARDS), and review factors affecting response to therapy, including the role of secondary prevention. Design: Trials were retrieved from the Cochrane Central Register of Controlled Trials (CENTRAL). Two investigators collected data on study characteristics, treatment intervention, and outcomes. The methodological quality of trials was determined and data were analyzed with Review Manager 4.2.3. Measurements and results: Five selected trials (n = 518) consistently reported significant improvement in gas exchange, reduction in markers of inflammation, and decreased duration of mechanical ventilation and intensive care unit stay (all p < 0.05). Two early small clinical trials showed marked reductions in the relative risk (RR) of death with glucocorticoid therapy (RR = 0.14, 95% CI 0.04-0.53; p = 0.004, I2 = 0%). Three subsequent larger trials, when combined, although nominally beneficial, did not reproduce the marked reductions observed in the earlier trials (RR = 0.84; 95% CI 0.68-1.03; p = 0.09, I2 = 9.1%), but achieved a distinct reduction in the RR of death in the larger subgroup of patients (n = 400) treated before day 14 of ARDS [82/214 (38%) vs. 98/186 (52.5%), RR = 0.78; 95% CI 0.64-0.96; p = 0.02, I 2 = 0%]. Conclusions: Prolonged glucocorticoid treatment substantially and significantly improves meaningful patient-centered outcome variables, and has a distinct survival benefit when initiated before day 14 of ARDS.

UR - http://www.scopus.com/inward/record.url?scp=38349070821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349070821&partnerID=8YFLogxK

U2 - 10.1007/s00134-007-0933-3

DO - 10.1007/s00134-007-0933-3

M3 - Comment/debate

C2 - 18000649

AN - SCOPUS:38349070821

VL - 34

SP - 61

EP - 69

JO - Intensive Care Medicine

JF - Intensive Care Medicine

SN - 0342-4642

IS - 1

ER -